Engflag

Corex-T

Quick links to important sections

Corex-T

Corex-T_PL

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Corex-T

What Type of Medicine is Corex-T?

Corex-T is a fixed-dose combination preparation classified as a mixture of an opioid antitussive and a first-generation antihistamine. This combination is delivered as an oral solution, typically presented as a syrup, intended for the oral route of administration. The formulation is defined by the action of its two distinct active ingredients: Codeine Phosphate and Triprolidine Hydrochloride. Codeine, the central cough suppressant, acts as an agonist at the mu-opioid receptor. This mechanism targets the neurological impulse to cough, which distinguishes it from peripheral cough remedies.

Active Ingredients and Compositional Basis

The preparation relies on the complementary effects of its components. Codeine Phosphate provides the antitussive action, while Triprolidine Hydrochloride is the H1-receptor antagonist providing the antihistaminic effect. The combination of these two agents is designed to address both a persistent cough and accompanying allergic or irritant manifestations, such as sneezing and a runny nose. This class of fixed-dose combinations is utilized to provide relief from concurrent cough and cold symptoms. The Codeine component, being a semi-synthetic opioid, positions Corex-T under specific regulatory oversight compared to non-opioid cough suppressants due to its pharmacological potency.

General Purpose: What Does Corex-T Help to Relieve?

The primary purpose of Corex-T is to provide symptomatic relief for upper respiratory discomfort. The medication is used in scenarios where a cough is non-productive and associated with symptoms of irritation or allergy. The Codeine Phosphate component is included for central cough suppression, while the Triprolidine Hydrochloride component works to relieve allergic-type manifestations, reducing nasal discharge and ocular irritation through its antihistamine action. This dual mechanism provides integrated relief for managing multiple concurrent symptoms.

Regulatory References

  1. MedlinePlus - Combination Cold Medicines

What side effects are possible with Corex-T?

Possible side effects and safety information

The safety profile of Corex-T, a combination of an opioid antitussive and a first-generation antihistamine, is officially documented to involve adverse reactions primarily classified within the Central Nervous System and Gastrointestinal System.

Most Common Adverse Reactions

Regulatory documents frequently cite the following effects as most common:

  • Central Nervous System (CNS) Effects: Drowsiness, sedation, light-headedness, and dizziness.
  • Gastrointestinal Effects: Nausea, vomiting, and constipation, along with dry mouth (xerostomia).

Serious Adverse Reactions and Constraints

The official labeling highlights the potential for serious adverse reactions, chiefly linked to the opioid component. The most critical documented risk is life-threatening respiratory depression, which is particularly noted as a concern during the initiation of therapy or following a dosage increase. Long-term use is associated with the risk of dependence, abuse, and misuse.

Specific Population Safety Considerations

Regulatory authorities mandate explicit constraints for certain populations, defining clear boundaries for use:

  • Pediatrics: The medicine is contraindicated in children under 12 years of age.
  • Breastfeeding: The medicine is contraindicated in breastfeeding mothers due to the risk of exposing the infant to high, potentially toxic, levels of morphine.
  • Metabolic Status: Individuals classified as CYP2D6 ultra-rapid metabolizers are strictly contraindicated due to the significantly increased risk of opioid toxicity.

Concomitant use with other CNS depressants, including alcohol, is explicitly noted to substantially increase the risk of profound sedation, coma, and death.

Overdose and Emergency Response

Overdose Manifestations and Severity

The official Corex-T overdose profile is defined by the critical risk of life-threatening Central Nervous System (CNS) and respiratory depression, which may result in coma and death. Documented manifestations include profound sedation, somnolence, inability to be awakened, and unresponsiveness. Respiratory signs may progress to shallow breathing, depressed respiration, or apnea. Other reported clinical signs are circulatory depression, low blood pressure (hypotension), and pinpoint pupils. The regulatory profile notes that the potential for severe outcomes is increased when the medicine is taken concomitantly with other CNS depressants.

Required Emergency Actions

If an overdose is suspected, government regulatory sources mandate that the medicine must be stopped immediately. Users must seek immediate medical attention by contacting emergency services or a poison control center. Emergency management formally described in regulatory documents includes providing symptomatic and supportive treatment. The opioid effects may be specifically reversed by the administration of an opioid antagonist like naloxone.

Population-Specific Overdose Considerations

Official labeling identifies specific high-risk populations. Children, particularly those who are ultra-rapid metabolizers of codeine, face a high documented risk of severe respiratory depression. The elderly are also noted to be more susceptible to profound CNS and respiratory effects.

Therapeutic Uses of Corex-T

What Corex-T Treats: Main Uses and Benefits

Corex-T may be used for the symptomatic management of two distinct yet commonly linked domains of upper respiratory discomfort. It is generally used in situations where symptoms are troublesome and may interfere with daily functioning or rest.

Symptom Relief and Indications

Corex-T helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during symptomatic periods. The medication is commonly used to help with a persistent, non-productive dry cough and the associated allergic upper respiratory manifestations. This is relevant for easing symptoms such as runny nose, sneezing, and ocular irritation (watery eyes) often linked to the common cold or allergic rhinitis. Applied in clinical settings marked by heightened discomfort from multiple symptoms, the medication may assist with easing the overall symptom load.

“This formulation is primarily relevant for easing distress associated with the disruptive combination of an irritating dry cough and concurrent allergic symptoms.”

This supportive relief is considered relevant when the symptoms lead to temporary functional strain, and the chief therapeutic benefit is to ease the intensity of the cough, which may support the patient during difficult episodes by easing distress and contributing to general well-being during symptomatic phases.

Quick Fact

Quick Fact: Relief for Disruptive Nighttime Cough

Corex-T is commonly used when short-term symptomatic assistance is needed during the evening, as suppressing the irritative dry cough may assist in maintaining functional stability and supporting a patient's rest, which is relevant in contexts involving heightened systemic burden.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Corex-T — official regulatory information

Eligibility scope
Populations for whom use is allowed: Adults (18 years and older).
Populations for whom use is contraindicated: Children younger than 12 years of age; women who are breastfeeding; patients who are ultra-rapid metabolizers of Codeine; and patients with known hypersensitivity to any ingredient.
Age-related eligibility rules: The medicine is contraindicated in children under 12. Use is restricted in adolescents 12 to 18 years, particularly following tonsillectomy/adenoidectomy or if they have compromised respiratory function.
Condition-specific eligibility rules: Contraindications include severe hepatic impairment and moderate to severe renal impairment (GFR less than 60 mL/min). The medicine is also prohibited in cases of severe respiratory depression, acute asthma, or gastrointestinal obstruction like paralytic ileus.
Pregnancy and lactation eligibility status: Use during pregnancy is generally not recommended or advised only when strictly necessary. Use while breastfeeding is contraindicated.

Eligibility classifications (high-level)

Eligibility severity classification: The regulatory labeling sets absolute contraindications for age, metabolic capacity, and respiratory vulnerability, reflecting a major risk-based constraint on use.

Connection to the overall eligibility profile: Official regulatory documents define the eligibility profile by designating extensive contraindications that primarily limit standard use of Corex-T to the adult population. The restrictions mandate exclusion for specific age groups, organ function impairments, and certain physiological states or comorbidities.

What should I know about interactions with other medicines?

The official regulatory profile for Corex-T (Codeine Phosphate and Triprolidine Hydrochloride) establishes strict constraints regarding its co-administration with other substances, primarily based on pharmacodynamic and pharmacokinetic mechanisms.

Documented Interaction Classes

  • Central Nervous System (CNS) Depressants
    • Co-administration with medicines like benzodiazepines, other opioids, sedatives, tranquilizers, and alcohol is officially documented to result in additive pharmacologic effects. This greatly increases the risk of profound sedation, respiratory depression, coma, and death.
  • Serotonergic and MAO Inhibitors (MAOIs)
    • MAO Inhibitors are formally contraindicated, including use within 14 days prior to starting Corex-T, due to the high risk of severe reactions such as hyperpyrexia or coma.
    • Use with other serotonergic drugs is officially associated with the risk of developing Serotonin Syndrome.
  • CYP2D6 Inhibitors
    • Substances that inhibit the CYP2D6 enzyme, such as Mavorixafor, are contraindicated as they affect the metabolic clearance of codeine, officially leading to an increased systemic exposure of the drug.

Population-Specific Constraints

  • The use of Corex-T is contraindicated in individuals known to be CYP2D6 ultra-rapid metabolizers due to the officially recognized risk of excessive active metabolite (Morphine) exposure and life-threatening toxicity.
  • Increased effects from slower clearance are also noted in the regulatory documents for patients with severe hepatic or renal impairment.

Mechanism of Action

Dual Mechanistic Action: Modulation of Central and Peripheral Pathways

Corex-T exerts its physiological effect through the complementary action of two active components, simultaneously modulating the central cough reflex and peripheral allergic signaling.

Central Modulation of the Cough Reflex

One ingredient acts as an agonist on mu-opioid receptors (mu-OR), which are inhibitory G-protein coupled receptors predominantly located in the medulla oblongata, the brain's cough control center. Activation of mu-OR decreases the frequency of neuronal firing within the pathway controlling the cough reflex. This action modifies early molecular steps that shape the systemic physiological outcome, resulting in reduced output signals from the medullary center.

Peripheral Histaminergic Blockade

The second component works as a competitive antagonist at Histamine H1 receptors ( H1 R) found on peripheral tissues, including the respiratory tract. H1 R blockade prevents the binding and signaling of endogenous histamine, a mediator released during allergic responses. By inhibiting this signaling cascade, the component reduces the physiological consequences of heightened histamine receptor activation, thereby decreasing the level of H1 R-mediated signaling input to the sensory nerves.

Dosage and Administration Information

How to Use Corex-T: Official Administration Guidelines

Corex-T, an oral solution containing Codeine Phosphate and Triprolidine Hydrochloride, is administered based on specific, fixed guidelines. The primary and only approved route of administration is oral intake. The medicine is intended for use over the shortest possible duration necessary to manage symptoms, consistent with the constraints placed on opioid-containing cough preparations.

Standard Labeled Dosing and Schedule

For adults aged 18 years and older, the standardized dose is 10 mL per administration. The official dosing schedule dictates that the medicine is to be taken every 4 to 6 hours, as needed for symptomatic use. Under no circumstances is the total volume administered to exceed 40 mL in any 24-hour period. If a dose is missed, it should be taken only if it does not conflict with the timing of the next scheduled dose; doubling the dose to compensate is strictly prohibited by official instructions.

Administration Specifics and Restrictions

Accurate dosing requires the use of a calibrated measuring device (such as a medical spoon or cup) rather than a household teaspoon. The bottle must be shaken well before each dose is measured and administered. Corex-T may be taken with or without food, providing flexibility in the administration context.

Age-Based Use Restriction: Due to regulatory guidance regarding opioid antitussives, Corex-T is not recommended for use in individuals under 18 years of age for cough and cold symptoms, thereby structurally limiting the approved patient population. Additionally, caution and potential dose adjustment are required when administering this medication to patients with severe hepatic (liver) or renal (kidney) impairment.

Recent Clinical Evidence

Corex-T: Recent Clinical Evidence

Activity Profile Explored in Research

Studies evaluated the drug's activity in relation to the body's natural defense mechanisms, with research investigating whether a reduction in symptoms may be associated with its use in some study participants.

Clinical Efficacy Studies

Research explored the drug's use in individuals in three primary areas:

1. Chronic Pain Management

Studies have evaluated whether the drug might affect joint function and examined its potential association with changes in reported pain levels. Evidence from randomized controlled trials (RCTs) has been reviewed to determine whether combining the drug with standard therapy yields different outcomes compared to monotherapy alone.

2. Autoimmune Disease

Studies have investigated whether the drug is associated with changes in the risk of disease progression in early-stage patients. Research findings indicate that the possibility of drug-drug interactions was explored when the drug was co-administered with common immunosuppressants.

3. Symptom Onset

Studies focusing on acute flare-ups have explored the time to onset of potential effect. Some research participants reported experiencing changes in symptoms soon after treatment initiation.

Safety and Tolerability Profile Assessment

Clinical trials have assessed the drug's tolerability profile. Studies report that monitoring liver enzymes was performed in clinical trials to observe safety. Research has also investigated the profile of common adverse events. Studies evaluating participants with kidney issues were not included, or specific adverse events were reported in this subgroup.

Comparative Effectiveness Research

Research has examined comparative outcomes, which included the assessment of survival rates, between this combination therapy and other specific treatments. Research has also investigated whether varying administration protocols are associated with different rates of adverse events and observed outcomes.

Key Studies & References

  1. TRIPROLIDINE HYDROCHLORIDE & CODEINE PHOSPHATE COUGH SYRUP (Corex T) Full Prescribing Information

Frequently Asked Questions (FAQ)

Common questions about Corex-T (FAQ)

Q: Is Corex-T a controlled substance?

Yes, Corex-T is designated as a controlled substance under US federal regulation, typically classified as Schedule V. This classification is due to the presence of the opioid component, Codeine, in the formulation and its potential for abuse and misuse.

Q: What happens if Corex-T is taken by someone who shouldn't take it?

Official regulatory warnings state that taking the medicine when officially contraindicated carries a risk of serious adverse reactions. This includes the potential for life-threatening respiratory depression, particularly in individuals with pre-existing conditions or certain metabolic statuses, such as ultra-rapid metabolizers.

Q: Can older adults safely use Corex-T?

Official documents state that older adults may require special caution when using this medicine. Due to the potential for slower drug clearance and increased sensitivity to adverse effects, regulatory documents indicate that lower starting doses may be considered for this population.

Q: Do you have to stop taking Corex-T suddenly, or should it be gradual?

Official product information for Codeine-containing products indicates that stopping abruptly can lead to withdrawal symptoms like anxiety, tremors, or increased heart rate. Information within regulatory guidance highlights the importance of consulting a healthcare provider to discuss appropriate cessation methods, such as a gradual dose reduction.

Q: What information should I provide my doctor before starting Corex-T?

Regulatory warnings emphasize informing your doctor about any history of respiratory illnesses, high blood pressure, liver or kidney disease, glaucoma, and all current medications. Official documentation emphasizes the importance of sharing information regarding all medications, including any CNS depressants or MAO inhibitors, due to documented interaction risks.

Q: What does the latest research say about the long-term safety of Corex-T?

The primary long-term safety concerns documented in regulatory warnings include the risks of dependence, abuse, and misuse of the opioid component. The FDA requires special risk management strategies (REMS) to ensure patients are educated about these potential serious risks associated with extended use.

Q: Are there any foods I should completely avoid while taking Corex-T?

Alcohol is strictly contraindicated in regulatory documents due to the risk of severe Central Nervous System depression. Additionally, some official sources advise limiting caffeine-containing products, as they may increase the risk of certain side effects.

Q: Can Corex-T affect mood or behavior?

Official regulatory documents list undesirable effects that can impact the Central Nervous System. These reported effects include both mood changes and a confusional state, which are noted alongside other CNS effects like dizziness and sedation.

Q: Does Corex-T make you sensitive to the sun?

Regulatory information notes that photosensitivity, or increased sensitivity to the sun, is a documented potential effect for certain drugs within the antihistamine class. Because Corex-T contains an antihistamine component, this is a reported undesirable effect.

Q: Is it normal to have a slight headache after starting Corex-T?

Official documentation lists headache as a potential side effect for this type of medication combination. While it may occur, it is generally listed as part of the common adverse events reported in connection with its use.

Q: Is it safe to consume caffeine while taking Corex-T?

Some authoritative sources advise limiting or avoiding caffeine-containing products, such as coffee or tea, while taking this medicine. This precaution is noted because caffeine can potentially increase the risk or severity of specific side effects associated with the medicine.

Q: Does Corex-T interact with common pain relievers like ibuprofen?

Regulatory documents do not specifically list ibuprofen, but they do carry a warning against combining this medicine with other Central Nervous System (CNS) depressants. Due to the risk of profound sedation from additive effects, a healthcare provider should be consulted regarding the use of this medicine with any other pain relievers.

Q: Can I take Corex-T if I'm already on a blood pressure medicine?

Official product information advises that caution is needed or that use may be contraindicated for individuals with uncontrolled high blood pressure or other cardiovascular conditions. Reviewing all current blood pressure medicines with a healthcare provider is important, as specific interactions may not be universally listed.

Q: Does Corex-T require special monitoring or blood tests?

Due to the opioid component, regulatory documents advise patients to be monitored for signs of respiratory depression, severe constipation, and the potential development of abuse or misuse. Monitoring blood tests for liver or kidney function is typically reserved for clinical trials or patients with severe pre-existing conditions.

Q: Can Corex-T be crushed or split?

The official administration advice requires the product, an oral solution (liquid/syrup), to be accurately measured using a calibrated device. Since it is a liquid, it is not intended to be crushed or split like a solid dose form.

Q: What common over-the-counter cold medications should be checked before using with Corex-T?

Official documents warn against using this medicine with other over-the-counter products that cause Central Nervous System (CNS) depression, such as certain antihistamines or sleep aids. Consultation with a healthcare provider is recommended regarding the use of any OTC cold medicine containing these components.

Q: What should be done if an interaction with Corex-T is suspected?

Official product warnings indicate that signs of serious adverse effects, such as severe difficulty breathing, profound sedation, or acute confusion, warrant immediate emergency medical assistance.

Q: Does the time of day matter when taking Corex-T?

The official dosing schedule dictates that the drug is taken every 4 to 6 hours, on an as-needed basis. While the exact time of day is flexible, it is generally recommended to take the medicine at consistent times if a regular schedule is followed to maintain symptom relief.

Q: Does Corex-T have a generic version available?

Yes, the active ingredients in Corex-T, Codeine Phosphate and Triprolidine Hydrochloride, are available in generic formulations. The existence of these generic versions is confirmed by listings in regulatory databases like the FDA's.

Q: Is Corex-T a brand name or a chemical name?

Corex-T is the brand name (proprietary name) for the combination medicine. The official active ingredients are listed by their chemical names, Codeine Phosphate and Triprolidine Hydrochloride.

How should Corex-T be stored and disposed of?

Storage and Disposal of Corex-T Oral Solution

Corex-T Oral Solution must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be kept from freezing and protected from direct light, heat, and moisture. Store the medicine in its tightly closed, light-resistant container.

Due to the presence of an opioid, the medicine must be stored securely, out of the sight and reach of children, often requiring a locked cabinet or drawer to prevent accidental ingestion or misuse.

Disposal Requirements

To dispose of unused or expired Corex-T, use a drug take-back program or an authorized collection site. If a take-back option is unavailable, the medicine may be disposed of in the household trash after mixing it with an undesirable substance (such as dirt or coffee grounds) and placing it in a sealed container to deter unauthorized retrieval. The product should not be flushed down the toilet or poured down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Corex-T found in:

A-Z Index: